Please try another search
SAN DIEGO - Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology firm focused on creating drug-Fc conjugate (DFC) immunotherapies, has announced new data from nonclinical...
- Multispecific CD73/PD-1 DFC demonstrates improved tumor reduction compared to PD-1 monotherapy in nonclinical study - CCR5-targeting DFC demonstrates potent efficacy in...
Cidara Therapeutics, Inc. (Nasdaq: NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Technical Indicators | Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Filter Table By:
Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
---|---|---|---|---|---|
Emerging Patterns | |||||
Belt Hold Bearish | 30 | Current | |||
Completed Patterns | |||||
Bullish doji Star | 1D | 1 | Apr 17, 2024 | ||
Three Inside Up | 30 | 1 | Apr 18, 2024 20:00 | ||
Dragonfly Bearish | 15 | 2 | Apr 18, 2024 20:15 |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
IAG | 169.80 | 187.90 | 163.55 | +9.10 | +5.66% | 35.30M | 18/04 | ||
Rolls-Royce Holdings | 402.50 | 406.71 | 398.30 | +1.10 | +0.27% | 34.65M | 18/04 | ||
EasyJet | 530.00 | 547.00 | 526.40 | +11.80 | +2.28% | 15.43M | 18/04 | ||
Lloyds Banking | 51.00 | 51.30 | 50.62 | +0.58 | +1.15% | 95.48M | 18/04 | ||
BP | 512.40 | 515.10 | 508.20 | -4.40 | -0.85% | 36.63M | 18/04 | ||
Ocado | 350.00 | 350.50 | 3.48 | +1.80 | +0.52% | 3.54M | 18/04 | ||
Centamin | 128.10 | 129.50 | 120.10 | -1.60 | -1.23% | 10.66M | 18/04 | ||
Barclays | 183.98 | 183.98 | 181.14 | +4.04 | +2.25% | 72.90M | 18/04 | ||
HSBC | 644.60 | 645.60 | 637.60 | +8.50 | +1.34% | 44.84M | |||
BAE Systems | 1,287.00 | 1,316.50 | 1,272.50 | -33.00 | -2.50% | 11.50M | 18/04 |
Cidara Therapeutics, Inc. is a biotechnology company. The Company is focused on the discovery, development and commercialization of therapeutics designed for patients facing serious diseases. The Company's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. The Company’s primary focus is using its Cloudbreak platform to develop a potential new class of drugs called drug-Fc conjugates (DFCs), for the prevention and treatment of serious diseases. This technology couples’ potent inhibitors to a human antibody fragment to create long-acting DFCs designed to inhibit multiple disease targets. Its advanced DFC program is CD388, a long-acting antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials.
Read MoreAre you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review